Pre-implantation genetic testing in ART: who will benefit and what is the evidence? by unknown
REVIEW
Pre-implantation genetic testing in ART: who will benefit
and what is the evidence?
Alberto Vaiarelli1 & Danilo Cimadomo1,3 & Antonio Capalbo1,2 & Giovanna Orlando1 &
Fabio Sapienza1 & Silvia Colamaria1 & Antonio Palagiano4 & Carlo Bulletti5 &
Laura Rienzi1,2 & Filippo Maria Ubaldi1,2
Received: 1 June 2016 /Accepted: 25 July 2016 /Published online: 5 August 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Pre-implantation genetic diagnosis for aneuploidy
testing (PGD-A) is a tool to identify euploid embryos during
IVF. The suggested populations of patients that can benefit
from it are infertile women of advanced maternal age, with a
history of recurrent miscarriages and/or IVF failures.
However, a general consensus has not yet been
reached.After the clinical failure of its first version based on
cleavage stage biopsy and 9 chromosome-FISH analysis,
PGD-A is currently performed by 24 chromosome screening
techniques on trophectoderm (TE) biopsies. This approach
has been clearly demonstrated to involve a higher clinical
efficiency with respect to the standard care, in terms of
sustained pregnancy rate per transfer and lower miscarriage
rate. However, data about PGD-A efficacy calculated on a per
intention-to-treat basis, as well as an analysis of its cost-effec-
tiveness, are still missing.TE biopsy is a safe and extensively
validated approach with low biological and technical margin
of error. Firstly, the prevalence of mosaic diploid/aneuploid
blastocysts is estimated to be between 0 and 16%, thus largely
tolerable. Secondly, all the comprehensive chromosome
screening (CCS) technologies adapted to, or designed to con-
duct PGD-A are highly concordant, and qPCR in particular
has been proven to show the lowest false positive error rate
(0.5 %) and a clinically recognizable error rate per blastocyst
of just 0.21 %.In conclusion, there is a sufficient body of
evidence to support the clinical application of CCS-based
PGD-A on TE biopsies. The main limiting factor is the need
for a high-standard laboratory to conduct blastocyst culture,
biopsy and vitrification without impacting embryo viability.
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Introduction
Pre-implantation genetic diagnosis (PGD) in assisted repro-
ductive technologies (ART) is suited to many inheritable ge-
netic disorders caused by a known mutation and chromosome
structural abnormalities, in order to increase the chance of
delivering a healthy baby. However, the application of PGD
is nowadays mainly focused on aneuploidy testing (PGD-A)
in order to identify chromosomally normal embryos for the
transfer. Since its first report in 1990 [1], PGD has always
been considered a very intriguing but controversial topic, es-
pecially since PGD-A (or BPGS^ as it has been referred to up
to now) started to represent the vast majority of cases [2, 3].
The group of patients that have been suggested throughout
the years to potentially benefit from PGD-Awere infertile or
sub-fertile women of advanced maternal age (AMA; usually,
defined as ≥ 35 years), with a history of recurrent pregnancy
loss (RPL; usually at least three previousmiscarriages) or with
repeated implantation failure (RIF; three or more failed em-
bryo transfers) and severe male factor [4]. Over time, other
indications have been proposed including a previous geneti-
cally abnormal pregnancy, poor embryo quality, previous
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radiotherapy and single embryo transfer (SET), even though a
general international consensus has not been built yet.
Chromosomal aneuploidies are indeed the main reason for
pregnancy loss and implantation failure, and their prevalence
in the embryo is strongly related to female age [5, 6].
The ultimate goal of PGD-A is to reach the same efficacy
of a standard IVF cycle, that is, the same number of babies
born on a per intention-to-treat basis, meanwhile increasing
the efficiency especially in terms of safety.
The aim of this review is to report Bthe state of the art^ in
the clinical validation and application of PGD-A.
The failure of PGD-A in its first version
In 2011, Mastenbroek et al. [7] published a review and meta-
analysis of all the randomized controlled trials (RCTs) pub-
lished up to that date that compared aneuploidy testing versus
standard IVF. They reported no beneficial effect of the former
on the live birth rate. On the contrary, especially AMA pa-
tients were shown to have an even lower chance of conceiving
when performing a PGD-A cycle. The authors proposed that
some technical drawbacks could be the cause of such a failure
and encouraged a careful pre-clinical validation of any novel
PGD-A approach before its implementation in IVF. Such a
negative outcome was ascribed to the strategy adopted at that
time to conduct chromosomal analysis, namely single/double
blastomere(s)-based 9 chromosome FISH analysis. Firstly,
FISH analysis itself is highly limited since just 9 out of the
24 chromosomes composing the human karyotype were ana-
lyzed, which means that all the aneuploidies, which at that
stage of embryo development can affect any chromosome,
are ignored [8]. Secondly, the already low resolution of the
techniques is also impacted by the pitfalls related to single-cell
analysis. The combination of these two drawbacks led to high
technical variability, over-estimation of mosaicism and an un-
diagnosed embryo rate as high as 10 % [9–12]. Thirdly,
cleavage-stage biopsy strongly impacts embryo viability and
its implantation potential, as Scott et al. well demonstrated in
2013 [13] in their randomized paired non-selection study.
Specifically, they selected the two best quality embryos from
a cohort produced by good prognosis women (defined as fe-
males younger than 35 years and with a normal ovarian re-
serve) during a standard IVF cycle, one was randomized to be
biopsied while the other was left undisturbed. Both the em-
bryos were then transferred without analysing the biopsied
fragment. In case just one embryo implanted, then the finger-
printing data from the foetal DNAwas compared to the DNA
from the biopsied fragment in order to assess whether they
corresponded or not. This design led the authors to define a
39 % significant relative reduction in implantation rate after
cleavage-stage biopsy, which could then be classified as a
detrimental approach. Interestingly, by applying the same
study design to blastocyst stage biopsy, the authors reported
no impact of this approach on embryo reproductive potential,
since no difference in implantation rate was reported with
respect to undisturbed blastocysts.
The onset of PGD-A new version
A novel approach has been introduced after the several levels
of pre-clinical validation, we will go through hereafter: TE
biopsy at the blastocyst stage associated with comprehensive
chromosome screening (CCS) techniques, such as array-
Comparative Genomic Hybridization (aCGH), array-Single
Nucleotide Polymorphisms (aSNP), quantitative Polymerase
Chain Reaction (qPCR) and next-generation sequencing
(NGS). Although, in 2014 Mastenbroek and Repping [14]
published an opinion paper stating their concerns about a pre-
mature widespread application also of this novel strategy.
Here, they drew attention to several points: the need to express
PGD-A results on a per intention to treat basis rather than on a
per embryo transfer basis, the need for unbiased and concor-
dant RCTs, the importance of evaluating the cost-
effectiveness of a PGD-A cycle, the estimation of the real
prevalence of chromosomal mosaicism, as well as the duty
to assess the sensitivity, specificity, positive and negative pre-
dictive values of any molecular method involved.
Hereafter, we will discuss the different types of evidence
produced up to date (Table 1 represents a summary of the
main published, as well as still missing evidences dealing
with this topic).
PGD-A effectiveness and efficacy
In a review published in 2015 [15], Lee and colleagues sum-
marized all the RCTs, observational and prospective studies
that approached CCS-based PGD-A in comparison to the
standard care. They were able to show that in both young
and AMA patient populations, PGD-A results in a higher de-
livery rate per embryo transferred. An equal clinical outcome
can be determined only via double embryo transfer in the
standard care group. To this regard, Forman and colleagues
[16, 17] in particular showed that single euploid blastocyst
transfer equals double untested embryo transfer in terms of
live birth rate, but with significantly better obstetrical out-
comes. In fact, they reported a lower birthweight and a longer
period spent in the Neonatal Intensive Care Unit for new-
borns from the standard care arm of the study. This was main-
ly a consequence of the establishment of multiple pregnancies
in the untested double embryo transfer group, which were
instead avoided by single euploid blastocyst transfers in the
PGD-A group.
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Dahdouh and colleagues and Chen and colleagues in 2015
published two meta-analyses [18, 19] of the RCTs and obser-
vational studies that adopted CCS-based PGD-A. They
showed that this approach results in a higher sustained implan-
tation rate per transfer, as well as lower miscarriage rate with
respect to the control. These data collectively represent a con-
siderable body of evidence in favour of PGD-A clinical effi-
ciency, even though it should be highlighted that the RCTs
published up to date were mostly performed in a good prog-
nosis patient population.
It should be acknowledged though that the efficacy of
PGD-A, namely the possibility to obtain the same delivery
rate per intention to treat with respect to the standard care, is
still to be demonstrated. Indeed, this is a critical aspect since it
would prove that by extending the culture to the blastocyst
stage, by performing TE biopsy and CCS, and by adopting a
freeze-all and SETstrategy, we are not causing any harm to the
intrinsic reproductive potential of the embryo itself. To this
regard, Ubaldi et al. in 2015 reported the clinical outcomes
in AMA patient population across the years characterized by
the gradual implementation of all these innovations in the
clinical practice and by the sharp increase of the overall rate
of the PGD-A cycles performed. Specifically, the cumulative
live birth rate per cycle was kept constant across this period,
while the miscarriage, and especially the multiple pregnancy
rates significantly decreased [20]. This paper represented the
first published evidence that the technical and procedural in-
novations in IVF (as PGD-A) do not impact its efficacy. Still
though, the value of these data is strongly limited by the ret-
rospective nature of the study. Multicentre RCTs comparing
PGD-A to the standard care, whose primary outcome should
be the delivery rate per intention to treat, are still eagerly
needed in this field and are currently in the pipeline. Only
the data produced through this study design can ultimately
solve this still controversial issue.
At last, an analysis of the cost-effectiveness of PGD-A is
also missing. Ideally, it should also take into account the ob-
stetrical and neonatal costs, especially in the standard care arm
of the study, where putatively higher miscarriage and multiple
pregnancy rates would be registered. The cost analysis is ob-
viously highly dependent on the molecular technique which is
adopted for aneuploidy testing and from the regional costs of
each type of medication, making such kinds of analysis of low
widespread reproducibility. Regardless, it is of critical impor-
tance to provide comparative data about the cost-effectiveness
of PGD-A in all the different settings in the future.
Biological source of error
An important concern in PGD-A is chromosomal mosaicism,
namely the presence in the same embryo of cells with different
karyotypes due to a mitotic error occurring after fertilization.
The earlier the mitotic error would occur along pre-
implantation development, the higher would be its extent in
the blastocyst. Its actual prevalence has still to be determined
in embryos and several reports in literature may have over-
estimated it, especially when based on single cell analysis at
the cleavage stage with biased and inefficient techniques. Two
concepts must be underlined: firstly, in a published dataset
which entailed 5337 consecutive chorionic villus samplings,
there was no difference in the prevalence of mosaicism at the
end of the first trimester in pregnancies conceived spontane-
ously compared to those from infertile couples. Furthermore,
there was no difference either in the prevalence of mosaicism
when in vitro (1.32 %) and in vivo treatments (1.22 %) were
compared in infertile couples, where the reported mosaicism
rate confirmed in a follow-up amniocentesis analysis was only
0.3–0.44 % [21]. Secondly, mosaicism will always represent a
source of biological variability where the analysis on a ran-
domly selected TE sample from a diploid/aneuploid blastocyst
Table 1 Levels of evidence of TE biopsy CCS-based PGD-A clinical
value
Trophectoderm biopsy + comprehensive chromosome aneuploidy testing
Higher effectiveness with respect to the standard care
Lee et al., 2015, systematic review
Dahdouh et al., 2015, meta-analysis
Chen et al., 2015, meta-analysis
Same efficacy as the standard care
Ubaldi et al.,2015, Retrospective analysis
Still unproven by prospective or randomized controlled trials
Higher cost-effectiveness with respect to the standard care
Still never reported
Tolerable prevalence of diploid/aneuploid blastocysts
Capalbo et al., 2013; 70 blastocysts; no preferential allocation of
aneuploid cells to the TE & 4 % diploid/aneuploid blastocysts
Northrop et al., 2010; 50 blastocysts; no preferential allocation of
aneuploid cells to the TE and 16 % diploid/aneuploid blastocysts
Johnson et al., 2010; 51 blastocysts; no preferential allocation of
aneuploid cells to the TE and 0 % diploid/aneuploid blastocysts
High positive and negative clinical predictive value
Scott et al., 2013, prospective randomised non-selection study (SNP-
array)
High concordance between CCS methods
Capalbo et al., 2016, propective validation study
Very low clinically recognizable error rate
Werner et al., 2014 (qPCR)
Tiegs et al., 2016 (aCGH)
Summary of the main published papers and their relative take-home mes-
sages to support a safe clinical application of TE biopsy CCS-based PGD-
A. Both the already existing, as well as the still missing, levels of evi-
dence have been summarized in this Table. ICM, Inner Cell Mass; TE,
trophectoderm; CCS, Comprehensive Chromosome Screening
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(the only one at risk of misdiagnosis) cannot mirror the actual
chromosomal constitution of the whole embryo.
People in the field were also concerned about the hypothesis
of a preferential allocation of aneuploid cells to the TE. There
are mainly three papers in literature that investigated this hy-
pothesis: in 2013, Capalbo et al. described a method to biopsy
the inner cell mass (ICM) that ensured 85.7 % of samples with
no TE cells contamination, and a contamination level lower
than 2 % in the rest [22]. Seventy blastocysts previously
analysed by aCGHwerewarmed and underwent to ICMbiopsy
as well as to the retrieval of 3 more TE fragments which were
then all analysed by FISH. No preferential allocation of aneu-
ploid cells to the TE was reported. In 2010, Northrop et al.
performed the aSNP-based blastocyst stage re-analysis of the
ICM and 3 TE fragments from 50 embryos that were previously
given an aneuploid diagnosis by cleavage stage FISH [23].
Also here, there was no report of a preferential allocation of
aneuploid cells to the TE. In the same year, Johnson et al. had
also performed a similar analysis by aCGH on the ICM and
2TE fragments from 51 blastocysts, again reporting no prefer-
ential allocation [24]. Furthermore, in these 3 papers, the prev-
alence of mosaic diploid/aneuploid blastocysts can be collec-
tively estimated around 5 %, thus largely tolerable.
Recently, Greco et al. reported to have transferred presumably
mosaic blastocysts diagnosed by aCGH to consenting patients
after counselling [25]. The authors stated that they were able to
identify 181 mosaic blastocysts out of 3802 analysed (4.8 %),
among which 18 were transferred to achieve 6 full-term healthy
pregnancies. This outcome suggests a scenario in which mosaic
blastocyst still does have the possibility to result in a clinical
pregnancy; however, the reliability of the molecular analysis
adopted in this study is somehow questionable and the diagnosis
of mosaicism can be partially ascribed to false positive errors of
aCGH, but we will discuss this issue in the next paragraph.
In a previous prospective randomised non-selection study
by Scott and colleagues [26], the authors already reported the
data derived from the SET of blastocysts that underwent the
biopsy of a TE fragment which was analysed only after the
definition of the clinical outcome downstream. In particular,
the clinical negative predictive value (the rate of CCS-
diagnosed aneuploid blastocysts that failed to implant) of
TE-based PGD-A through aSNP technology was reported as
93.5 %, while the positive predictive value (the rate of CCS-
diagnosed euploid blastocysts that resulted in a sustained im-
plantation) was reported as 48.2 %. Recently, the same group
has presented the data produced with the same design but after
a targeted NGS analysis-based approach (no whole genome
amplification involved) [27]. Importantly, 100 % of the blas-
tocysts that were assigned an aneuploid diagnosis (n = 41) did
not actually implant in their interim analysis.
In conclusion, although real mosaicism and methodologi-
cal aspects can impact the reliability of the diagnosis due to
false positive errors, up to date, there has been no evidence at
all from well-designed pre-clinical studies that this is a major
issue in the application of PGD-A as long as validated tech-
nologies are used for CCS.
Technical source of error
Every time a technique or embryo selection parameter is intro-
duced in clinical practice, it is pivotal to perform a validation, as
well as an analysis of the level of accuracy in terms of speci-
ficity and sensitivity. Both the advantages and the limitations of
this should be clearly expressed to the patients (). To this regard,
all the CCSmethods adapted to or designed to perform PGD-A
showed very high consistency in the detection of whole chro-
mosome imbalances when compared in the blinded validation
study performed by Capalbo et al. and published in 2015 [28].
However, aCGHwas characterized in this study by a 7% false-
positive error rate (0.5 % in the case of qPCR), which may be a
consequence of the artefacts derived by the use of whole ge-
nome amplification (WGA). This approach in fact entails a
random amplification of the genome which can result in an
uneven amount of the DNA sequences at some genomic loca-
tions and consequently in technical artefacts. Such a pitfall is
instead prevented by targeted amplification protocols that are
limited to non-variable regions in the genome, as the ones that
characterize qPCR or targeted NGS [29, 30]. Obviously, these
last approaches result in a lower resolution since structural im-
balances and/or partial aneuploidies cannot be detected (array-
based orWGA-basedNGS approaches can), but they guarantee
an accuracy on embryo biopsies higher than 99 %. Importantly,
a validation on cell lines of known karyotype has been per-
formed for both aSNP and qPCR [28, 29, 31] and is instead
still missing for aCGH, despite this should be the very first level
of validation for any novel technique. A provocative consider-
ation is the possibility that not all the diagnoses of segmental
aneuploidies or mosaicism in studies that adopted WGA-based
technologies can be reliable and actually mirror the real chro-
mosomal status of the embryo. Rather, they can be an artefact of
WGA, which should be acknowledged by the providers. In our
opinion, it is dangerous to produce some data which still cannot
be interpreted with a sufficiently high level of accuracy, since it
can affect the overall efficacy of PGD-A as it occurred for its
first version.
In 2014, Werner et al. [32] published the data describing
the clinically recognizable error rate after qPCR-based CCS.
Here they showed a largely tolerable 0.21 % (10/4794) error
rate per blastocyst. In particular, 7 errors were found in the
product of conception (4 were due to real chromosomal mo-
saicism) and 3 resulted in a full-term delivery. In contrast, in
2016, Tiegs et al. reported a 0.9 % (5/579) error rate per blas-
tocyst analysed after aCGH-based PGD-A [33]. Similar re-
ports are still eagerly needed for all the other molecular tech-
niques adopted for PGD-A.
1276 J Assist Reprod Genet (2016) 33:1273–1278
Indications to PGD-A and guidelines according
to the international societies
The Canadian Society of Obstetrics and Gynaecology encour-
aged not to perform the PGD-A strategy entailing the FISH-
based analysis of blastomeres in favour of the CCS-based analy-
sis of TE biopsies. The latter is in fact reported here as the gold
standard approach due to the favourable clinical outcomes it en-
sures [34]. The authors endorsed PGD-A application particularly
for good prognosis patients since it may result in an improvement
with respect to the standard criteria for embryo selection.
The US Assisted Reproductive Technology Surveillance
Data of years 2011–2012 were published in 2016 [35]. Here,
the authors support the higher safety of PGD-Awith respect to
the standard care in terms of lower odds of miscarriage and,
for patients older than 37, the higher likelihood of achieving a
live-birth delivery per transfer. To this regard, PGD-A was
strongly recommended for patients aged older than37.
What the indications to PGD-A should be is still a contro-
versial topic. It is generally indicated for AMA patients, even
though a threshold of age has not been defined yet. Franasiak
et al. [36] reported on more than 15,000 CCS-screened TE
biopsies an exponential increase in the aneuploidy rate from
35 years of maternal age onwards, which rises to 90 % by the
age of 44. Based on this data, most of the blastocysts obtained
in this patient population are aneuploid and thus not reproduc-
tively competent. The identification of the euploid blastocysts
is a pivotal tool because we can avoid useless and potentially
dangerous transfers. To this end, the tailoring of ovarian stim-
ulation is crucial and novel strategies such as double stimula-
tion in a single menstrual cycle (Duostim) [37] in poor prog-
nosis patients could result in a higher possibility to obtain an
euploid embryo in the shortest possible time.
Finally, Franasiak et al. [36] also reported a 30 % baseline
production of aneuploid embryos in very young patients
(<35 years). This evidence suggests the possibility to extend
PGD-A application to good prognosis patients who produce a
high number of blastocysts, especially if they have an history of
previous IVF failures (RIF) and/or miscarriages (RPL). This
can reduce the number of blastocysts candidate to the transfer
and support a SET policy also in this patient population.
Furthermore, the systematic application of PGD-A in allegedly
good prognosis patients holds the potential to identify a sub-
group of patients that produce a significantly higher rate of
aneuploid embryos than what is expected on the basis of female
age only. This is extremely important in a context where no
biomarker is yet available to predict such an outcome.
At last, RCTs that investigate the value of PGD-A in purely
RPL and purely RIF patients are also missing. They are eagerly
needed though, in order to assess whether aneuploidy screening
can increase the efficiency of IVF also in such a poor prognosis
population, where maternally derived embryonic aneuploidies
eventually are not the main cause of infertility.
Conclusions
Nowadays and ever since PGD-Awas introduced in the clinical
practice, the counselling given to a couple has changed dramat-
ically. In particular, the primary aim now is not to perform the
transfer of an excellent/good quality embryo anymore, especial-
ly since themorphological quality is onlymildly correlatedwith
euploidy rate [8], but to identify a blastocyst with a high repro-
ductive potential. PGD-A is a tool which can enhance our pre-
dictive power of the clinical outcomes because, once an euploid
blastocyst is obtained, the patient is provided with a ≈ 50 %
sustained implantation potential across the border of female
age and independently from embryo morphological/
morphodynamic quality. Good prognosis patients who produce
many blastocysts can also then benefit from aneuploidy screen-
ing since it could potentially shorten the time required to per-
form the transfer of the competent embryo(s).
A high-standard laboratory is required to successfully im-
plement a PGD-A programme. In particular, we should be
able to guarantee a proper culture system to maximize blasto-
cyst rate, proper embryo grading parameters so as not to dis-
card viable embryos, an efficient vitrification technique to
minimize degeneration after warming, skilled embryologists
to conduct TE-based biopsy and proper CCS techniques with
the lowest possible no amplification, false-positive and nega-
tive error rates. All these aspects are essential so as not to
reduce the efficacy of IVF and, overall, they represent the
main limiting factor for an extensive application of PGD-A
worldwide.
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